Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibito...
Trazodone is indicated for the treatment of major depressive disorder (MDD). It has been used off-label for adjunct therapy in alcohol dependence, and off-label to treat anxiety and insomnia. It may also be used off-label to treat symptoms of dementia, Alzheimer’s disease, schizophrenia, eating disorders, and fibromyalgia due to its effects on various neurot...
Parkwood Institute, London, Ontario, Canada
National Jewish Health, Denver, Colorado, United States
Penn State University, Hershey, Pennsylvania, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Keck Hospital of the University of Southern California, Los Angeles, California, United States
Parkwood Institute Mental Health Care Building, London, Ontario, Canada
Sleep Disorders Research Program Brigham and Women's Hospital, Boston, Massachusetts, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
The Chinese University of Hong Kong, Hong Kong, Hong Kong
Queen's University, Kingston, Ontario, Canada
Keck Hospital of the University of Southern California, Los Angeles, California, United States
University of Missouri, Columbia, Missouri, United States
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
University of Virginia, Charlottesville, Virginia, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.